Nektar Therapeutics sell kalki
Start price
11.07.20
/
50%
€21.14
Target price
04.11.21
-
Performance (%)
-9.58%
End price
14.03.21
€19.11
Summary
This prediction ended on 14.03.21 with a price of €19.11. With a performance of -9.58%, the SELL prediction by kalki was trending in the right direction. kalki has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Nektar Therapeutics | -8.662% | -8.662% | 97.295% | -92.022% |
iShares Core DAX® | -2.385% | 3.986% | 16.836% | 16.377% |
iShares Nasdaq 100 | -4.527% | -0.258% | 18.824% | 29.987% |
iShares Nikkei 225® | -4.129% | 4.382% | 10.912% | -1.507% |
iShares S&P 500 | -2.885% | 1.387% | 20.391% | 35.258% |
Comments by kalki for this prediction
In the thread Discuss Nektar Therapeutics
Sell Nektar Therapeutics